Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit

Omid Azimaraghi(Beth Israel Deaconess Medical Center), Matthias Eikermann(Albert Einstein College of Medicine), Peter Santer(Beth Israel Deaconess Medical Center), Maximilian Hammer(Apple (Israel)), Maximilian S. Schaefer(Beth Israel Deaconess Medical Center), Karuna Wongtangman(Albert Einstein College of Medicine), Sandra Rumyantsev(Beth Israel Deaconess Medical Center), Xinling Xu(Beth Israel Deaconess Medical Center), Patrick M. Fuller(Beth Israel Deaconess Medical Center), Katharina Platzbecker(Beth Israel Deaconess Medical Center), Stephanie D. Grabitz(Johannes Gutenberg University Mainz), Balachundhar Subramaniam(Beth Israel Deaconess Medical Center), Maria D. Patrocínio(Beth Israel Deaconess Medical Center), Friederike C. Althoff(Goethe University Frankfurt)
BMJ Open
July 1, 2020
Cited by 9


Related Papers